Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma - Full Text View

Sponsored by:	Actelion
Information provided by:	Actelion
ClinicalTrials.gov Identifier:	NCT00070590

Purpose

Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.

Condition	Intervention	Phase
Pulmonary Fibrosis Scleroderma, Systemic	Drug: Bosentan	Phase II Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis

Resource links provided by NLM:

MedlinePlus related topics: Pulmonary Fibrosis Scleroderma

Drug Information available for: Bosentan

U.S. FDA Resources

Further study details as provided by Actelion:

Primary Outcome Measures:

Change from baseline to End-of-Study in 6-minute walk distance.

Secondary Outcome Measures:

Time to death (all causes) or to worsening of PFTs up to End-of-Study.
Worsening of PFTs (on 2 consecutive tests at least 4 weeks apart) is defined as: decrease from baseline ≥ 10% in FVC OR decrease from baseline ≥ 15% in DLco AND ≥ 6% in FVC

Estimated Enrollment:	132
Study Start Date:	July 2003
Study Completion Date:	September 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Main inclusion criteria:

Systemic Sclerosis diffuse or limited
Significant Interstitial Lung Disease on HRCTscan
DLco < 80% predicted
Dyspnea on exertion
Walk not limited by musculoskeletal reasons

Main exclusion criteria:

Interstitial Lung Disease due to other conditions than SSc
End stage restrictive or obstructive lung disease
Severe cardiac or renal diseases
Significant pulmonary arterial hypertension
Smoker (> 5cig./day)
Treatment with immunosuppressive, antifibrotic drugs, high dose corticosteroids (within 4 weeks of randomization)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00070590

Show 29 Study Locations

Sponsors and Collaborators

Actelion

More Information

No publications provided

Study ID Numbers:	AC-052-330, BUILD 2
Study First Received:	October 6, 2003
Last Updated:	January 29, 2009
ClinicalTrials.gov Identifier:	NCT00070590 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Actelion:

Scleroderma
Fibrosing alveolitis
Build
bosentan

Study placed in the following topic categories:

Lung Diseases, Interstitial
Fibrosing Alveolitis
Skin Diseases
Fibrosis
Sclerosis
Cardiovascular Agents
Antihypertensive Agents
Pulmonary Fibrosis

Bosentan
Respiratory Tract Diseases
Lung Diseases
Connective Tissue Diseases
Scleroderma, Diffuse
Scleroderma
Scleroderma, Systemic

Additional relevant MeSH terms:

Lung Diseases, Interstitial
Skin Diseases
Fibrosis
Cardiovascular Agents
Antihypertensive Agents
Pulmonary Fibrosis
Pharmacologic Actions

Bosentan
Pathologic Processes
Respiratory Tract Diseases
Lung Diseases
Therapeutic Uses
Connective Tissue Diseases
Scleroderma, Systemic

ClinicalTrials.gov processed this record on September 03, 2009